Michael Koslowski
Director Ejecutivo en Kling Biotherapeutics BV .
Cargos activos de Michael Koslowski
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Kling Biotherapeutics BV
 Kling Biotherapeutics BV BiotechnologyHealth Technology Kling Biotherapeutics BV is a clinical-stage biotechnology company based in the Netherlands. The Dutch company has developed a pipeline that evaluates B cells in individuals with remarkable responses to cancer and infectious diseases. Kling Biotherapeutics' proprietary B cell immortalization platform enables rapid functional screening of antibodies, leading to the identification of several antibodies targeting novel epitopes and cancer-associated antigens with unique post-translational modifications. Michael Koslowski has been the CEO of the company since 2022. | Director Ejecutivo | 12/12/2022 | - |
Historial de carrera de Michael Koslowski
Antiguos cargos conocidos de Michael Koslowski.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Director Técnico/Científico/I+D | - | - |
Formación de Michael Koslowski.
| Universität des Saarlandes | Undergraduate Degree |
| Universität zu Köln | Doctorate Degree |
Estadísticas
Internacional
| Alemania | 3 |
| Países Bajos | 2 |
| Reino Unido | 2 |
Operativa
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Kling Biotherapeutics BV
Kling Biotherapeutics BV BiotechnologyHealth Technology Kling Biotherapeutics BV is a clinical-stage biotechnology company based in the Netherlands. The Dutch company has developed a pipeline that evaluates B cells in individuals with remarkable responses to cancer and infectious diseases. Kling Biotherapeutics' proprietary B cell immortalization platform enables rapid functional screening of antibodies, leading to the identification of several antibodies targeting novel epitopes and cancer-associated antigens with unique post-translational modifications. Michael Koslowski has been the CEO of the company since 2022. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Koslowski
- Experiencia
